➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
McKinsey
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 6,524,851

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,524,851
Title: Hybrid nucleic acid molecules and vectors including .beta.-globin regulatory elements
Abstract:The invention relates to hybrid nucleic acid molecules for gene therapy in cells of the erythroid lineage, and in particular .alpha.-, .beta.-, .delta.-, .epsilon., .gamma.-, or .zeta.-globin nucleotide sequences operably linked to .beta.-globin regulatory elements. The hybrid nucleic acid molecules, at single copy, are capable of producing a polypeptide. The hybrid nucleic acid molecules are useful for treatment of hemoglobinopathies such as sickle cell anemia or .beta.-thalassemia. The hybrid nucleic acid molecules are useful at single copy for erythroid expression at single copy of RNA and polypeptides in transgenic animals.
Inventor(s): Ellis; James (Toronto, CA)
Assignee: HSC Research and Development Limited Partnership (Toronto, CA)
Application Number:09/411,449
Patent Claims:see list of patent claims

Details for Patent 6,524,851

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial HSC Research and Development Limited Partnership (Toronto, CA) 2018-10-01 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial HSC Research and Development Limited Partnership (Toronto, CA) 2018-10-01 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial HSC Research and Development Limited Partnership (Toronto, CA) 2018-10-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Johnson and Johnson
McKesson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.